Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 482 results for anxiety

  1. Anaphylaxis: assessment and referral after emergency treatment (CG134)

    This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.

  2. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  3. Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (HTG687)

    Evidence-based recommendations on artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images.

  4. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  5. Pregnancy and neonates: newborn blood spot test communication with 6 weeks of movement in (IND67)

    This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of notification of movement in. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG86

  6. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  7. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.

  8. Babies, children and young people's experience of healthcare (NG204)

    This guideline describes good patient experience for babies, children and young people, and makes recommendations on how it can be delivered. It aims to make sure that all babies, children and young people using NHS services have the best possible experience of care. It is recognised that parents and carers play a key role, and where appropriate, we took their views into account when developing the recommendations.

  9. Personality disorders: borderline and antisocial (QS88)

    This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.

  10. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

  11. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

    Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

  12. Afamelanotide for treating erythropoietic protoporphyria (HST27)

    Evidence-based recommendations on afamelanotide (Scenesse) for treating erythropoietic protoporphyria in adults.

  13. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

    Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.

  14. Epilepsy: annual review (IND227)

    This indicator covers the percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM209

  15. Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (HTG623)

    Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. This involves opening the chest through the breastbone and wrapping a mesh around the outside of the aorta at the part closest to the heart.